Exhibit 99.1 BIOPHARMA Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 Compassionate/Expanded Use Access Program with 6 additional patients under evaluation Additional LNC platform work in inflammation and oncology completed; Company evaluating next step ...

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 Compassionate/Expanded Use Access Program with 6 additional patients under evaluation Additional LNC platform work in inflammation and oncology completed; Company evaluating next steps Conference call begins at 4:30 p.m. Eastern time today BEDMINSTER, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Matinas B ...

Financial Performance - For the six months ended June 30, 2024, the net loss was $11,543, compared to a net loss of $11,573 for the same period in 2023[61]. - No revenue was generated during the three and six months ended June 30, 2024, while $1,096 was generated in contract research revenue during the same periods in 2023[62]. - Total revenues for the six months ended June 30, 2024, were $0, compared to $1,096 in the same period of 2023, primarily due to the absence of contract research revenue[78]. - Cash used in operating activities for the six months ended June 30, 2024, was $(8,875), an increase from $(6,280) in the same period of 2023[81]. - Net cash provided by financing activities for the six months ended June 30, 2024, was $9,242, compared to $(5) in the prior year, driven by proceeds from a registered direct offering[84]. Research and Development Expenses - Total research and development expenses for the three months ended June 30, 2024, were $3,371, a decrease of 5.3% from $3,559 in the same period of 2023[74]. - The total research and development expenses for the six months ended June 30, 2024, were $6,817, compared to $7,530 for the same period in 2023, reflecting a decrease of 9.5%[65]. - Research and Development (R&D) expenses for the six months ended June 30, 2024, were $6,817, a decrease of 9.5% from $7,530 in the same period of 2023[77]. - Research and development expenses are anticipated to increase over time as product candidates move into later stages of clinical development[66]. General and Administrative Expenses - General and administrative expenses for the three months ended June 30, 2024, were $2,468, down from $2,600 in the same period of 2023[67]. - General and Administrative (G&A) expenses for the six months ended June 30, 2024, were $4,925, down 7.3% from $5,311 in the prior year[77]. Future Outlook and Concerns - The company expects to incur additional operating losses for the foreseeable future and has substantial doubt about its ability to continue as a going concern[61]. - The company has incurred operating losses since inception and does not expect to generate product revenue for many years[62]. - The company expects to incur significant expenses and increasing operating losses for the foreseeable future, particularly related to clinical studies and product development[85]. - There is substantial doubt about the company's ability to continue as a going concern beyond the next twelve months without additional funding[86]. - The company anticipates financing its cash needs through a combination of equity offerings, debt financings, and collaborations[87]. Funding and Cash Position - As of June 30, 2024, the company had unrestricted cash, cash equivalents, and marketable debt securities totaling $14,313[78]. - The company raised a total of $166,907 in gross proceeds from equity securities since inception, with net proceeds of $153,445[78]. - The company relies on collaborations and licensing arrangements to fund operations, which may not be available on acceptable terms[61]. - The company plans to advance MAT2203 into the ORALTO trial for the treatment of invasive aspergillosis, aiming to establish a pharmacodynamic bridge for further indications[58].

BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business ...

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at N ...

Dr. David Perlin is the inaugural Chief Scientific Officer and Executive Vice President for the Hackensack Meridian Center for Discovery and Innovation, which seeks to rapidly translate innovations in science to improve outcomes for patients with cancer, infectious diseases, autoimmune and other acute and chronic disorders. He is an expert in drug discovery and drug-resistance mechanisms, and has helped develop novel therapeutics and diagnostics against high-threat bacteria, viruses and fungi. He has publis ...

BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston. T ...

Matinas BioPharma Hldgs (NYSEMKT:MTNB) just reported results for the first quarter of 2024.Matinas BioPharma Hldgs reported earnings per share of -3 cents. This met the analyst estimate for EPS of -3 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to a ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners Operator Welcome, everyone, to the Matinas BioPharma First Quarter 2024 Financial Results Conference Call. Currently, al ...

Exhibit 99.1 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track Company's strategy to expand its LNC platform into inflammation and oncology supported by favorable in vivo data in multiple disease models Conference call begins at 4:30 p.m. Eastern ti ...